Nektar Therapeutics (NKTR) Misses Q4 EPS by 3c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $68.36 +1.45%
EPS Growth %: -215.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
ALZN, ASPU, USAU, More
EPS Growth %: -215.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.57), $0.03 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $39.8 million versus the consensus estimate of $45.92 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Empress Royalty acquires Tongon gold stream for $62M
- Rexford Industrial closes $1.2B portfolio sale to EQT Real Estate
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
